Cladribine and CLL
In this randomised phase III study, the efficacy and safety of cladribine and fludarabine, two purine analogues, were compared. Patients (n = 233) with chronic lymphocytic leukaemia were randomised to receive cladribine,
fludarabine or chlorambucil for six cycles along with health-related quality-of-life assessments. The primary end point was overall survival (OS). Results showed that while there was no statistical difference among the treatment arms for OS, median progression-free survival (25, 10, 9 months) and median time to second treatment (40, 22, 21 months) were superior with cladribine. For more information, click here to read the full article.